昆明做人流哪里医院好(昆明怀孕14周引产) (今日更新中)

UNITED NATIONS, Jan. 26 (Xinhua) -- China on Wednesday welcomed the smooth development of the south Sudan referendum, voicing its hope that the parties in south and north Sudan could reach a consensus at an early date on the outstanding issues through dialogue and consultations.Li Baodong, the Chinese permanent representative to the United Nations, made the statement in an interview with Xinhua after he spoke at the UN Security Council about the Chinese stance on the situation of Sudan.Earlier on Wednesday, the Security Council met to hear briefings from Atul Khare, UN assistant secretary-general for peacekeeping operations, and Ibrahim Gambari, the joint special representative of the African Union-United Nations Mission in Darfur (UNAMID), on the current situation in Sudan."China welcomes the smooth development of the south Sudan referendum, this is the result of the joint efforts of north and south Sudan and the international community," Li said."At present, priority should be given to the following work: First, continuous efforts should be made to fully maintain peace and stability in Sudan to enable the country to realize its long- term peace, stability and development," he said. "Second, efforts should be made to encourage the parties in south and north Sudan to continue their efforts for the full implementation of the Comprehensive Peace Agreement (CPA), particularly for a consensus at an early date on the outstanding issues."The referendum, with its week-long polling period ending on Jan. 15, will determine whether south Sudan remains a part of Sudan or becomes independent, in accordance with the 2005 CPA that ended a long-running north-south civil war.The referendum's preliminary results are expected to be announced by Feb. 2, and depending on whether appeals are launched in the courts, the final result will be declared on Feb. 7 or 14.

KIGALI, Feb. 8 (Xinhua) -- Li Zhaozhuo, vice chairman of the National Committee of the Chinese People's Political Consultative Conference (CPPCC), will head a high-level delegation to Rwanda this month to boost friendly and cooperative ties between the two countries.According to a statement released by Rwanda's Senate on Tuesday, the three-day visit will begin on Feb. 18 and is to strengthen regular contacts between Rwandan and Chinese parliamentary chambers on a number of issues and review bilateral projects.Chinese Ambassador to Rwanda Shu Zhan has confirmed that the official delegation from China is "planning an outreach visit" to Rwanda.After a meeting with the Chinese envoy to Rwanda on Tuesday, the president of Rwanda's Senate, Vincent Biruta, said his country's legislative chambers would continue to promote friendly ties with the CPPCC and play a "constructive role" in promoting bilateral cooperation.Rwanda have received training assistance from China in the applications of information communication technology (ICT) in parliaments.The Central African nation has a long-standing bilateral relationship with China in a number of socio-economic areas such as infrastructure, energy, education, health, agriculture and communications.

BEIJING, Feb. 28 (Xinhua) -- Construction began on China's first low-speed maglev line Monday in Beijing, a project that will make China only the second country with a low-speed maglev line after Japan.The project marked China's ability to industrialize low-speed maglev technologies, said Chang Wensen, father of China's maglev technology and professor at the National University of Defense Technology.The 10-kilometer line runs from Shimenying Station in west Beijing's Mentougou District to Pingguoyuan Station in the Shijingshan District.The line, a section of Line S1 on the Beijing subway network, is expected to be completed in 2013 with a designed speed of 100 to 120 km per hour.China's research of maglev technologies was started in the 1980s by a team led by Chang Wensen. A 204-meter test line in central China's Hunan Province and a 1.5-km test line in north China's Hebei Province were built jointly by Beijing Maglev Technology Development Co., Ltd. and National University of Defense Technology.The intensity of the magnetic field had been tested as safe, according to a test report of Institute of Electrical Engineering, Chinese Academy of Sciences.The cost of the low-speed maglev line was estimated at 300 million yuan (4.6 million U.S. dollars) per kilometer, slightly more than light rail, but cheaper than the subway, which cost more than 600 million yuan a kilometer, said Li Jie, director of technology research center of National University of Defense Technology.The technology was also under consideration for Line 8 of the subway network in Shenzhen, in south China's Guangdong Province, said Liu Zhiming, board chairman of Beijing Maglev Technology Development Co., Ltd.."If Shenzhen adopts the technology, Line 8 will be China's second low-speed maglev line," he said.The world's first low-speed maglev line, at 8.9 km long, was completed in Japan in March 2005.Maglev, short for magnetic levitation, technology uses a large number of magnets to lift and propel a vehicle, making it faster, quieter and smoother than conventional wheeled transport systems.High-speed maglev vehicles can reach speeds of 450 km per hour and are usually used in long distance transportation, while low-speed maglev lines are usually used in short distance transportation.Construction also began on another seven lines on the Beijing subway network Monday.With an investment of 82 billion yuan (12 billion U.S. dollars), the eight lines will total 113.7 km in length and are expected to open from 2013 to 2015.Beijing has 16 lines under construction.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

来源：资阳报